These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11811565)

  • 1. Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women.
    Ott SM; Oleksik A; Lu Y; Harper K; Lips P
    J Bone Miner Res; 2002 Feb; 17(2):341-8. PubMed ID: 11811565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.
    Zheng S; Wu Y; Zhang Z; Yang X; Hui Y; Zhang Y; Chen S; Deng W; Liu H; Ekangaki A; Stocks J; Harper K; Liu J
    Chin Med J (Engl); 2003 Aug; 116(8):1127-33. PubMed ID: 12935394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].
    Zheng SR; Wu YY; Zhang ZL; Yang X; Hui Y; Zhang Y; Chen SL; Den WH; Liu H; Ekangaki A; Stocks J; Harper K; Liu JL
    Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):226-9. PubMed ID: 12885371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
    Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
    J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.
    Draper MW; Flowers DE; Huster WJ; Neild JA; Harper KD; Arnaud C
    J Bone Miner Res; 1996 Jun; 11(6):835-42. PubMed ID: 8725181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
    Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW
    Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
    Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
    J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
    Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
    J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
    Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety assessment of raloxifene over eight years in a clinical trial setting.
    Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
    Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.
    Arlot M; Meunier PJ; Boivin G; Haddock L; Tamayo J; Correa-Rotter R; Jasqui S; Donley DW; Dalsky GP; Martin JS; Eriksen EF
    J Bone Miner Res; 2005 Jul; 20(7):1244-53. PubMed ID: 15940379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men.
    Doran PM; Riggs BL; Atkinson EJ; Khosla S
    J Bone Miner Res; 2001 Nov; 16(11):2118-25. PubMed ID: 11697809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
    J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.